Calidi Biotherapeutics Secures $3 Million Investment from Dr. Ronald Rigor for Nova Cell Subsidiary Development and Oncology Pipeline Expansion
San Diego-based biotechnology company, Calidi Biotherapeutics, has announced a strategic investment of $2 million from Dr. Ronald Rigor into its newly established subsidiary, Nova Cell, Inc. This investment is intended to accelerate the development of Calidi’s Adult Adipose Allogeneic (AAA) stem cell innovative programs. In addition to the investment in Nova Cell, Dr. Rigor has also invested an additional $1 million into Calidi to further bolster its oncology pipeline of assets.
With a vision to revolutionize targeted antitumor virotherapies, Calidi Biotherapeutics has been making significant strides in the field of biotechnology. By leveraging genetic engineering and the power of stem cells, the company aims to develop innovative treatments that can effectively target and eradicate cancer cells.
The $2 million investment from Dr. Ronald Rigor into Nova Cell, the new subsidiary of Calidi, is a testament to the potential of Calidi’s AAA stem cell program. These cutting-edge stem cell therapies utilize adipose tissue-derived stem cells, which have shown immense promise in treating various diseases, including cancer. By harnessing the regenerative properties of these stem cells, Calidi aims to develop personalized and highly targeted therapies for cancer patients.
The investment from Dr. Rigor will enable Calidi to advance the development of Nova Cell’s programs, giving them the necessary resources to conduct further research, pre-clinical trials, and potential clinical trials. This financial infusion will help accelerate the timeline for bringing these innovative therapies to patients, providing them with new treatment alternatives that have the potential to significantly improve their quality of life.
Moreover, Dr. Rigor’s additional $1 million investment into Calidi’s oncology pipeline demonstrates his confidence in the company’s broader vision and portfolio of assets. This capital injection will enable Calidi to expand its ongoing efforts in developing breakthrough oncology treatments. The company’s pipeline includes multiple candidates that harness the power of oncolytic viruses and immune-based therapies to specifically target and eliminate cancer cells.
Calidi Biotherapeutics’ innovative approach to cancer treatment has garnered considerable attention in the biotechnology sector. The strategic investment by Dr. Ronald Rigor not only provides much-needed financial support but also serves as an endorsement of Calidi’s cutting-edge research and development endeavors.
This investment will fuel Calidi’s mission to make significant advancements in the fight against cancer, offering patients hope for more effective treatments. By combining the expertise of Calidi Biotherapeutics with the financial support from Dr. Rigor, the company is poised to accelerate its progress towards transforming the field of oncology.
Comments